| Ytd | 45.14% | |
| 1y | -58.96% |
| Open | 19.72 | Prev Close | 19.47 | Low | 19.09 | High | 19.92 | Mkt Cap | 1.60B |
| Vol | 1.12M | Avg Vol | 1.08M | EPS | -3.88 | P/E | N/A | Forward P/E | -5.61 |
| Beta | 1.04 | Short Ratio | 6.90 | Inst. Own | 79.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 18.20 | 200-d Avg | 17.34 | 1yr Est | 27.62 |
MLTX News
Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ:MLTX) with a Outperform and rais
MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and stron
U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates
MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology compa
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
MoonLake reported durable one-year Phase 3 hidradenitis suppurativa data for sonelokimab and plans a
SAGTEC GLOBAL (NASDAQ: SAGT) gained 75.6% in pre-market trading after projecting 35% revenue growth
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradeni
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy a
On May 22, 2026, MoonLake Immunotherapeutics (the "Company") entered into a Master Commercia